Condition
Advanced Malignant Mesothelioma|Epithelial Mesothelioma|Recurrent Malignant Mesothelioma|Sarcomatous Mesothelioma
Estimated Enrollment: 13
Age Group: 18 Years and older (Adult, Senior)
Gender: All
Study Type: Interventional
Study Design Allocation: Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment
Study ID Numbers: NCI-2012-02839|PHII 67|N01CM62209
Study First Received: August 16, 2006
Last Updated: December 17, 2014
Estimated Primary Completion Date: March 2009
Primary Outcome Measures:
Objective Tumor Response Rate According to the Response Evaluation Criteria in Solid Tumors (RECIST) Committee|Overall Survival|Time to Progression|Toxicity Profile as Assessed by the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) Version 3.0.|Apoptosis by TUNEL Assay|Histone Acetylation by IHC and Western Blotting
Sponsors and Collaborators:
National Cancer Institute (NCI)
Website Link: https://ClinicalTrials.gov/show/NCT00365053
